May 10, 2011

Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction: REVEAL: A Randomized Controlled Trial

.   .   

This randomized controlled trial in non-CKD patients with STEMI examined the impact of a single intravenous bolus of epoetin alfa within 4 hours of PCI.  The intervention group did not have any reduction in infarct size and was associated with higher rates of adverse cardiovascular events.

Should this trial impact how Nephrologists prescribe ESA in CKD or dialysis patients immediately post-MI?

Related Articles:

Anemia, Internal Medicine for Nephrologists
  • Pablo Amair

    I did not like the article about use of EPO after MI. EPO was designed only to treat anemia and is an excellent treatment, it was not designed to use in MI. The results are not in contradiction to using EPO in anemia treatment.